Prana Biotechnology today announced that the Journal of Huntington’s Disease has in its December, 2012 edition, published data showing the benefits of PBT2 in Huntington Disease*. The paper describes PBT2’s ability to inhibit the development of the symptoms and pathological features of Huntington Disease in pre-clinical transgenic animal models.
Prana Biotechnology today announced that it has completed recruitment in the Reach2HD Phase IIa clinical trial using PBT2 in patients with Huntington Disease (HD).
Prana Biotechnology today announced that the New York Academy of Sciences eBriefing which provides information and video footage of the symposium which took place on November 29th titled “Targeting Metals in Alzheimer’s and Other Neurodegenerative Diseases” is now available for viewing by the public by going to: www.nyas.org/MetalsandAD-eB. The eBriefing features multimedia presentations of speakers’ slides and audio, written meeting summary, and links to related resources.
Prana Biotechnology today announced that Prana’s Chairman and CEO, Geoffrey Kempler, will provide a company overview and update at the Cowen & Company 33rd Annual Health Care Conference on Monday, March 4, 2013 at 2:50 pm ET at The Boston Marriott Copley Place in Boston, MA.
Prana Biotechnolo today announced the upcoming presentation of new data demonstrating the ability of PBT2 to reduce the damage to brain cells, caused by the accumulation of the tau protein and preventing subsequent cognitive impairment. The tau protein, along with the Abeta protein, are the two major proteins associated with Alzheimer’s Disease.
Prana Biotechnology today announced that PBT434, Prana’s lead drug candidate for Parkinson’s disease (PD) and movement disorders, will be presented at two international conferences in March. The key finding to be reported is that PBT434 reduces the aggregation and accumulation of a key protein (alpha- synuclein) in multiple transgenic animal models of the disease.
Following on from the announcement released on 4th March, 2013 and at the request of the Australian Securities Exchange, the company is pleased to provide further detail in respect to the presentation of the new data demonstrating the ability of PBT2 to reduce the damage to brain cells, caused by the accumulation of the tau protein and preventing subsequent cognitive impairment.
Prana Biotechnology, today announced that it has secured funding of A$7 million through a placement of approximately 35.9 million fully paid ordinary shares at a price of A$0.195 per share (equivalent to approximately US$2.03 per Nasdaq listed ADR).
Prana Biotechnology today reported on the progress of its lead development asset PBT2 in Phase II trials for Huntington disease and Alzheimer’s disease. Across the two trials approximately 37% have been dosed to 6 months or longer, twice the duration of the previous Phase II Alzheimer’s trial . 1,2 PBT2 has been well tolerated and both trials are on schedule with very pleasing retention rates and compliance. Each Independent Data Safety Monitoring Board for the two trials met at the end of March and recommended that each trial continue as planned without any protocol changes.